Innovative Cancer Diagnostics Lucence's proprietary AI-powered liquid biopsy technology positions it as a leader in early cancer detection, creating opportunities to partner with healthcare providers and diagnostic labs seeking advanced, non-invasive testing solutions.

Strategic Collaborations Recent partnerships with Mayo Clinic, NCCS Singapore, and DxD Hub highlight Lucence’s expanding network and credibility, presenting potential sales avenues through health systems and research institutions interested in cutting-edge cancer diagnostics.

Expanding R&D Efforts Ongoing initiatives like the UNITED 2.0 project and collaborations to develop clinical-grade profiling tests indicate significant growth in product pipeline, ideal for engaging in early discussions on integrating new diagnostic tools.

Global Market Presence With dual headquarters in Palo Alto and Singapore, and partnerships across Asia and the US, Lucence offers an opportunity to explore international markets and tailor solutions for diverse healthcare systems worldwide.

Financial Growth & Investment Backed by over US$80 million in funding and substantial revenue, Lucence's financial strength suggests capacity for strategic investments or collaborative funding models to accelerate sales and product adoption.